Schizophrenia 1 - Clinical (1)

[P133] Factors associated with continuation of paliperidone palmitate 1-month formulation monotherapy in patients with schizophrenia.

*Tatsuro Marumoto¹, Hiroshi Horio¹, Hiroaki Kinoshita², Natsuko Morita², Tokiko Touma³, Kyoko Takebe², Akihide Wakamatsu¹ (1. Medical Affairs Division, Janssen Pharmaceutical K.K., 2. Drug Safety Surveillance Department, Japan Safety & Surveillance Division, Janssen Pharmaceutical K.K., 3. Statistics & Decision Sciences Japan, Janssen Pharmaceutical K.K.)

キーワード：paliperidone palmitate 1-month formulation, LAI monotherapy, schizophrenia